Background Although there were criteria for diagnosis of neuromyelitis optica (NMO) and multiple sclerosis (MS), it is still difficult to differentiate NMO from MS, due to the overlapping clinical manifestations. Therefore it is necessary to characterize clinical features of NMO and MS patients in the mainland of China, to simplify the process of disease diagnosis, and to identify criteria for the differential diagnosis of NMO and MS. Methods A total of 138 Chinese Han patients from the mainland of China including 73 NMO, 60 MS and 5 MS-like patients with positive NMO-IgG were included in the study. Clinical records were reviewed retrospectively and the results of clinical examination, laboratory experiments, magnetic resonance imaging (MRI) and evoked potentials (EPs) were compared between NMO and MS patients. In addition, the relationship between the NMO-IgG serologic status and clinical characteristics were analyzed. Results Compared with MS patients (1.3: 1.0), more female prevalence was observed in NMO patients (4.2: 1.0; P=0.003). There were also statistically significant differences in visual EPs, oligoclonal bands, brainstem lesions in MRI and longitudinally extensive spinal cord lesions (LESCLs) between NMO and MS patients. Brainstem lesions observed in brain MRI were found in 17.9% of MS patients, over 3.7 times higher than in NMO patients (4.8%, P=0.024). When stratified NMO patients by NMO-IgG, LESCLs were found in 42.1% of NMO-IgG-negative NMO patients, over 3.5 times higher than in NMO-IgG-positive patients (11.9%, P=0.008). Statistical difference was also observed in CD4 + /CD8 + ratios between NMO-IgG-positive and -negative NMO patients. Conclusions Comprehensive analysis of MRI, laboratory and EPs data can facilitate differential diagnosis of MS and NMO. In addition, the combination of LESCLs and brain MRI findings failing to satisfy MRI criteria for MS is highly sensitive and specific for NMO.
N euromyelitis optica (NMO) and multiple sclerosis (MS) are common inflammatory demyelinating diseases affecting the central nervous system (CNS). Compared with European populations, classic MS is rare and NMO is more common in Asian populations. 1, 2 Due to the overlapping clinical manifestations, such as onset age, female predilection, optic neuritis and spinal syndrome, it is difficult to distinguish NMO and MS to some extent in Asian populations. [3] [4] [5] Hence, there is still an intensive debate concerning whether NMO is a specific entity or heterogeneous sub-group of MS. [6] [7] [8] [9] Compared with MS, NMO patients have a higher prevalence of optic neuritis, longitudinally extensive transverse myelitis (often affecting greater than 3 vertebral segments) and a higher positive rate of aquaporin-4 antibodies in serum, while the oligoclonal bands in NMO cases are usually negative. 9 Also, the treatment and prognosis for these two diseases are different, thus it is important to differentiate NMO from MS. 10 The diagnoses of NMO and MS are based on the combination of clinical manifestations, neuroimaging, laboratory examinations, and disease progression. 11, 12 It is still difficult to differentiate the two diseases in Asian populations when NMO serologic marker NMO-IgG is negative. 4, 5, 13 In this study, we compared clinical manifestations and the results of laboratory experiments, magnetic resonance imaging (MRI) and evoked potentials (EPs) between NMO and MS patients to characterize the clinical features of them in a cohort from the mainland of China, and we have identified some specific indicators which are useful for differentiating NMO from MS. 
METHODS

Patients
Comparison of NMO and MS patients
Medical records were reviewed retrospectively, physical and laboratory examinations were documented in detail. Cerebral spinal fluid (CSF) was collected for analyzing cell counts, total protein levels, IgG index and oligoclonal bands. MRI was performed to detect possible brain and spinal cord lesions. EPs including visual evoked potential (VEP), brainstem auditory evoked potential (BAEP) and somatosensory evoked potential (SEP) were also performed. Immunological indicators such as NMO-IgG, antinuclear antibody (ANA), double stranded (ds) DNA, antineutrophil cytoplasmic antibody (ANCA), lymphocytes subsets, and thyroid function were all analyzed. All these data were collected during the hospitalization and all patients were on a relapse course. MRIs were classified as normal or abnormal with nonspecific, MS-like or atypical abnormalities. EPs were classified as normal or abnormal based on the absence or presences of abnormalities in wavelength, amplitude, or latency.
Testing of serum AQP-4 antibodies
Serum AQP-4 antibodies were tested using an indirect immunofluorescence method described elsewhere. 14, 15 The results were scored as NMO-IgG positive or negative by two independent investigators. The serum samples were assayed unaware of the clinical diagnosis. No serum was classified as indeterminate or equivocal.
Testing of oligoclonal bands
Lumbar puncture and blood sampling were performed simultaneously. Samples were immediately frozen and stored at -80°C until investigation. Albumin and IgG concentrations were determined with an immunonephelometric method. The relative blood brain barrier (BBB) permeability for high molecular weight proteins was assessed by the CSF-to-serum albumin ratio. The evaluation of intrathecal synthesis was performed by calculation of the IgG index. The IgG index was considered normal under 0.7 g/L according to laboratory normal values.
Statistical analysis
All statistical analyses (mean ± standard deviation (SD)), significance of group differences (χ 2 -and t-tests) and correlations between variables were performed using the Statistical Program for Social Science statistical soft-ware (SPSS V16 for Windows, SPSS Inc., USA). P values <0.05 were considered to be statistically significant.
RESULTS
Demographic information and initial symptoms
All patients in this study had a relapsing course, and were recruited unbiased. There were more NMO patients in the present study, suggesting that NMO is more prevalent in Chinese. When analyzed the demographic information, NMO had a higher female to male ratio (4.2: 1.0) compared to MS (1.3: 1.0; P=0.003). We did not find statistical differences in onset age between the two groups. There were not any clinical signs that were unique to either disorder, but some were highly characteristic. Initial symptoms in NMO and MS patients are listed in Table 1 . Impaired vision and cervical pain presented more frequently in NMO patients, while gait disturbance, vertigo, dizziness and tremor were observed more frequently in MS patients.
Laboratory findings
Comparing laboratory findings, we found statistical differences in oligoclonal bands, IgG-index, and autoantibodies between NMO and MS patients, but no significant differences were found in CSF-white cell counts, total protein levels, destruction rate of blood brain barrier (BBB), function and antibodies of thyroid (except T3), or lymphocyte subtypes ( Table 2 ). Higher positive rates of detection of ANA and Sjögren's syndrome A (SSA) antibodies were found in the NMO group compared to the MS group (P=0.007; P=0.017). In addition, seven NMO patients tested positively for anti-Ro antibodies and one patient was positive for perinuclear antineutrophil cytoplasmic antibody (p-ANCA). None of these patients, however, had clinical manifestations of systemic autoimmune disease.
NMO-IgG antibody is a highly specific marker for NMO, with a sensitivity of 50%-75% and a specificity of 90%. 15, 16 In the present study, the positive rate of NMO-IgG was 68.7% in the NMO group. We furthered divided the NMO patients into NMO-IgG positive (+) and negative (-) groups. As shown in Table 3 , there is no statistical difference in laboratory findings between these two groups, except for the CD4 + /CD8 + ratio. 
MRI findings and EPs findings
In the MS group, brain MRI was not available from 4 patients who were diagnosed with MS in other hospitals and treated in our department. Among 56 patients with brain MRI, two had normal brain MRI, in which one had focal spinal cord lesion and the other had multiple cervical lesions. The prevalence of brain lesions was significantly higher in the MS group compared with the NMO group. The distribution of the brain lesions in both groups is shown in Figure 1 .
Spinal cord abnormalities were observed in 89.4% of NMO and 63.0% of MS patients (P=0.001). Longitudinally extensive spinal cord lesions (LESCLs) were observed in 22.7% of the NMO patients and none of the MS patients (Table 4 ). Comparing the NMO-IgG (+) and NMO-IgG (-) sub-groups of NMO patients, brain abnormalities were observed in 36.6% of the NMO-IgG (+) group, but 66.7% of the NMO-IgG (-) group (P=0.033) and there was a similar distribution of brain lesions in both groups ( Figure  2 ). Furthermore, LESCLs were observed more frequently in the NMO-IgG (-) group (P=0.008).
Comparing EPs findings, more VEP abnormalities were observed in NMO group (P=0.002), while there was no statistical difference between NMO-IgG (+) group and NMO-IgG (-) group (Table 4 ).
Special cases report
The clinical features of 5 MS-like patients with positive NMO-IgG are shown in Table 5 . After exclude other causes that may mimic the clinical and MRI findings of MS, each of them met 2005 Revised McDonald Criteria 14 except for the positive NMO-IgG. Three of them were diagnosed with primary progressive multiple sclerosis (PPMS). Three out of 5 patients received a spinal cord MRI examination, one had cervical lesions and the other two were normal. All patients received a brain MRI examination and showed cerebral white matter lesions. In addition, two patients showed brainstem lesions, specifically in a region enriched in AQP-4 channel. 17 Clinical features of nine NMO patients who were positive for oligoclonal bands (OB) are listed in Table 6 . Each of the patients met the 2006 revised Wingerchuk Criteria. 11 In addition, 10 patients in the NMO group were SSA-positive. Salivary gland biopsies were performed in 9 patients and coexistence of Sjögren's syndrome (SS) confirmed in 3 patients. 18 Among these three patients, two were NMO-IgG (+) and three were OB (+).
DISCUSSION
Previous studies have described differences in clinical and paraclinical features of NMO and MS patients between some Asian (Korean, Japanese, Chinese) and Caucasian populations. 13, [19] [20] [21] To our knowledge, the present study is the first comprehensive investigation of clinical, laboratory, MRI and EPs features of patients with NMO and MS in population from the mainland of China. Several of the clinical characteristics that we observed differ from a previous report from a Southern Chinese population 22 and previous studies on non-Chinese populations. 23, 24 In relation to the initial symptoms, the most common initial symptom in Japanese MS (including conventional MS and opticospinal MS) was loss of vision, 3 while in our study, gait disturbance, vertigo, dizziness and tremor were more frequently observed. Moreover, our observations are not completely consistent with studies based on western countries, 25, 26 which reported more sensory and motor dysfunctions. Among our NMO patients, 11 presented with neck pain, an unusual symptom rarely reported before. Differences in genetics and/or environment might play a role in the observed heterogeneity of symptoms.
Consistent with previous findings in Korean, 27 there is only 89.4% of NMO patients showed spinal cord lesions, this bias may result from the stage of disease when patients were recruited to our data. About 58% of NMO patients showed brain MRI abnormalities during their clinical follow-up periods, and most (66.7%) were NMO-IgG negative, suggested that there existed some differences in pathogenesis and progression between NMO-IgG positive and negative NMO patients, or there existed a co-location between NMO and MS, especially in NMO-IgG negative NMO patients. Lesions involving the hypothalamus were observed in MRI scans at similar rates in NMO and MS patients, consistent with a previous report that the hypothalamus is also frequently affected in MS. 28 The frequency of brainstem lesions in our MS group was higher than in the NMO group, and the distribution of lesions in the NMO-IgG positive group was similar to that of the negative group, suggesting no correlation between the localization of brain lesions and NMO-IgG positivity. This result is inconsistence with previous reports, which indicated that localization of AQP-4 in the brain, such as hypothalamus, brainstem, and periventricular is a marker for inductive lesions in NMO, 26, 29 suggesting that the NMO-IgG might play no role in the pathogenesis of brain lesions in NMO patients. In the present study, we did not find LESCLs in MS patients. However, it has been repeatedly reported in some Asian populations and Caucasian populations that LESCLs were not rare in patients diagnosed with MS. 1, 6, 13, 30 This difference might due to the definition of LESCLs used in our study: a spinal cord lesion that extends continuously over three or more vertebral segments, as observed in spinal cord MRIs. According to our results, LESCLs were observed more frequently in the NMO-IgG negative group. This observation is consistent with a previous report on Asian populations that patients with LESCLs had a lower rate of NMO-IgG positivity, 31 but inconsistent with a previous suggestion gained from Caucasian populations that there is a correlation between LESCLs and NMO-IgG positivity. 20, 32 This kind of bias might be caused by the including criteria of NMO patients, once the patient was NMO-IgG negative, there existed a LESCLs to satisfy the diagnosis criteria.
In addition, the role of anti-AQP4-antibodies in NMO pathogenesis is still unclear, 33 although the level of serum AQP-4 antibodies is widely considered to be a specific biomarker for distinguishing NMO patients from MS patients in western countries. 34 However, NMO-IgG positivity has previously been reported in some Asian MS patients. 13, 19, 21, 35 In the current study, five patients fulfilling diagnosis of MS and excluding for other causes that may mimic the clinical and MRI findings of MS, were NMO-IgG positive, suggesting a concurrence of NMO spectrum disorders (NMOSD) and MS in populations from the mainland of China, or NMO-IgG could also be found in some MS patients, especially in PPMS. One possible explanation is PPMS patients might have a similar pathogenesis and progressive to NMO. Moreover, the presence of NMO-IgG in MS patients might predict a primary progressed disease course. The result needs to be further confirmed in more studies in different ethnic populations.
In agreement with previous reports, 19, 36 we found statistically significant differences in OB, IgG-index, and VEP between NMO and MS patients. We also found that there were more NMO patients with multiple serum autoantibodies, including antinuclear antibodies and SSA-Abs. Based on previous studies 37, 38 and our results, multisystem autoimmune diseases and non-organ-specific autoantibodies are frequently observed in NMO.
In conclusion, our results demonstrate that clinical and paraclinical features of Chinese NMO and MS patients are significantly different from those observed in the Caucasian populations, and partly different from the Japanese population. Although there are many overlapping features between NMO and MS patients, the presence of impaired vision, cervical pain, NMO-IgG positivity, autoantibody positivity, VEP abnormalities and LESCLs, strongly suggest a diagnosis of NMO, while the presentation of initial symptoms of dizziness, tremor, gait disturbance or vertigo, combined with a CSF IgG-Index >0.7, OB positivity, and presence of brain MRI lesions localized in cerebral white matter, periventricular white matter and brainstem suggest a diagnosis of MS. Additionally, despite NMO-IgG negative, the combination of LESCLs and brain MRI findings failing to satisfy MRI criteria for MS is highly sensitive and specific for NMO. MS-like patients with NMO-IgG positive, indicated a more severe progressive prognosis, and need a long-term prednisone therapy and continuous disease modifying therapy, such as CTX and monoclonal antibody.
